NewsSource: EClinCloud

Live Webinar Preview | Applying eCOA to Achieve Patient-Centered Clinical Research

3 min readEClinCloud Editorial Team
Article image

Source: EClinCloud.

To encourage a patient-centered approach to new drug development, evaluate drug benefit-risk across more dimensions, and appropriately use patient-reported outcomes as endpoints, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has issued multiple guidance documents explicitly encouraging the use of electronic clinical outcome assessment (eCOA) / electronic patient-reported outcome (ePRO) tools in clinical drug research.


Article image


"Guiding Principles for Clinical Value-Oriented Clinical Development of Antitumor Drugs"


In November 2021, the CDE issued the "Guiding Principles for Clinical Value-Oriented Clinical Development of Antitumor Drugs," affirming that collecting PRO data in oncology patients can provide clinically important information that cannot be obtained from other measures or endpoints.


"Guiding Principles for the Application of Patient-Reported Outcomes in Drug Clinical Development (for Trial Implementation)"


In December 2021, the CDE issued the "Guiding Principles for the Application of Patient-Reported Outcomes in Drug Clinical Development (for Trial Implementation)," which notes that compared with paper-based PROs, ePRO offers clear advantages in data collection efficiency, real-time capability and flexibility, compliance, security, and patient privacy protection.


This means eCOA is gradually transitioning from an "initial phase" to a "mature application phase," providing important guidance for the use of ePRO and eCOA tools. This is a positive signal for the use of eCOA in clinical trials.


Moving from paper to electronic formats, the advantages of eCOA are reflected in patient experience, scientific rigor of data, and trial operational costs. Applying eCOA helps improve clinical trial efficiency and data quality, and—under a patient-centered premise—enables more effective patient management and more scientific clinical efficacy evaluation.


Article image



Nevertheless, for clinical trial leads at pharmaceutical companies or CROs, the following common questions remain when it comes to successfully delivering eCOA studies:


Which scales are needed for this study?

Are these scales already available in the eCOA scale library?

What is the value of eCOA compared with paper COA?

As source data, can eCOA data be modified?

What kind of eCOA system meets regulatory requirements?


To answer these questions, on March 3, 2023, from 16:00 to 17:00, EClinCloud will partner with the "Medicine Economic News" New Media Center to co-host the live online webinar "Applying eCOA to Achieve Patient-Centered Clinical Research." During the webinar, Ms. Xiong Ke, Senior Product Consultant at EClinCloud, will draw on her experience from a forward-looking perspective to provide pharmaceutical companies and CROs with a comprehensive introduction to eCOA.



01

Session Highlights

In-depth analysis of what eCOA is

The significance and value of eCOA for "patient-centered" clinical trials

Global regulatory authorities' perspectives on the use of eCOA

02

Target Audience

Practitioners and professionals in domestic R&D, regulatory affairs, clinical operations, and related pharmaceutical fields

03

Content Overview

Common issues in the implementation and use of electronic clinical outcome assessment (eCOA)


Article image





About EClinCloud

EClinCloud is a technology company dedicated to clinical research and development, providing an integrated, interoperable all-in-one cloud platform for clinical trials (including technology products such as CTMS, eTMF, EDC, RTSM, eCOA, and eConsent, as well as solutions such as scale management, linguistic validation, rater training, and data quality analysis) alongside clinical trial endpoint assessment technologies across therapeutic areas (including oncology, central nervous system, and ophthalmology). Combining advanced technology with life sciences data, EClinCloud is building a globally leading, patient-centered SaaS cloud platform for clinical evidence support to help domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.




Article image


Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.